Kimberly Low - Concepedia

Concepedia

Author

Kimberly Low

Cedars-Sinai Medical Center

Also Known As

K. Low, Kai En Low, Kimberly Low, Low Kimberly

27

Publications

1.1K

Citations

15

H-Index

20

Concepts

All Affiliations

Cedars-Sinai Medical Center Motility (United States)University of California, Los Angeles

KL

About

Kimberly Low is an author at Cedars-Sinai Medical Center specializing in gastroenterology, medicine, and antimicrobial resistance.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Gastroenterology	6	6	409
2	Medicine	5	5	246
3	Immunology	2	2	45
4	Microbiology	2	2	144
5	Health Sciences	1	1	129

Kimberly Low

×

16

Publications

1.1K

Citations

15

H-Index

	Year	Citations
The Degree of Breath Methane Production in IBS Correlates With the Severity of Constipation Soumya Chatterjee, Sandy Park, Kimberly Low, The American Journal of Gastroenterology	2007	229
Rifaximin versus Other Antibiotics in the Primary Treatment and Retreatment of Bacterial Overgrowth in IBS Janet Yang, Hyo-Rang Lee, Kimberly Low, Digestive Diseases and Sciences ProbioticDysbiosisPrimary TreatmentHealth SciencesAntibiotics	2007	129
Intestinal methane production in obese individuals is associated with a higher body mass index. Robert J. Basseri, Benjamin Basseri, Mark Pimentel, PubMed	2012	114
A Combination of Rifaximin and Neomycin Is Most Effective in Treating Irritable Bowel Syndrome Patients With Methane on Lactulose Breath Test Kimberly Low, Laura Hwang, Johnson Hua, Journal of Clinical Gastroenterology	2010	113
Evaluating Breath Methane as a Diagnostic Test for Constipation-Predominant IBS Laura Hwang, Kimberly Low, Reza Khoshini, Digestive Diseases and Sciences Functional Gastrointestinal DisorderPhysiologyGastroenterologyDigestive TractMicrobiome	2009	94
A New Rat Model Links Two Contemporary Theories in Irritable Bowel Syndrome Mark Pimentel, Soumya Chatterjee, Christopher Chang, Digestive Diseases and Sciences Contemporary TheoriesFunctional Gastrointestinal DisorderPhysiologyGastroenterologyDigestive Tract	2007	84
Efficacy of the glucagon-like peptide-1 agonist exenatide in the treatment of short bowel syndrome David C. Kunkel, Benjamin Basseri, Kimberly Low, Neurogastroenterology & Motility	2011	80
Role of Cytolethal Distending Toxin in Altered Stool Form and Bowel Phenotypes in a Rat Model of Post-infectious Irritable Bowel Syndrome Venkata B. Pokkunuri, Mark Pimentel, Walter Morales, Journal of Neurogastroenterology and Motility	2012	63
Polycystic Ovary Syndrome Is Associated with an Increased Prevalence of Irritable Bowel Syndrome Ruchi Mathur, Ara Ko, Laura Hwang, Digestive Diseases and Sciences Functional Gastrointestinal DisorderMedicineGastroenterologyGynecologyPolycystic Ovary Syndrome	2009	41
Low-dose nocturnal tegaserod or erythromycin delays symptom recurrence after treatment of irritable bowel syndrome based on presumed bacterial overgrowth. Mark Pimentel, Walter Morales, Sheila Lezcano, PubMed	2009	34

Page 1